Please login to the form below

Not currently logged in
Email:
Password:

CD3

This page shows the latest CD3 news and features for those working in and with pharma, biotech and healthcare.

Affimed rockets on $5bn-plus Roche immuno-oncology deal

Affimed rockets on $5bn-plus Roche immuno-oncology deal

ALL). A third drug from the platform – CD33/CD3 T cell engager AMV564 – has been licensed to US biotech Amphivena and is in phase I for the treatment of acute myeloid

Latest news

More from news
Approximately 1 fully matching, plus 12 partially matching documents found.

Latest Intelligence

  • Taking a lean and careful approach Taking a lean and careful approach

    Its fully human engineered CD3 antibody Foralumab has reached phase II with potential for a wide range of autoimmune and inflammatory diseases such as non-alcoholic steatohepatitis (NASH), primary biliary cholangitis,

  • Deal Watch June 2016 Deal Watch June 2016

    Both antibodies have a cytotoxic T-cell binding domain (CD3), which activates T-cells at the site of the tumour for killing of malignant cells, and a specific tumour antigen binding

  • Pharma deals during December 2014 Pharma deals during December 2014

    platform. The antibody targets both CD19 and CD3 and is being developed for the treatment of B-cell malignancies.

  • Deal Watch table for August 2014 Deal Watch table for August 2014

    187. Emergent BioSolutions/ Morphosys. Licence, joint development &commercialisation. MOR209/ES414, anti-PSMA/anti-CD3 bi-specific antibody targeting prostate cancer (preclinical).

  • Pharma deals during February 2014 Pharma deals during February 2014

    CD123 and CD3.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics